Chronic back pain frequently stems from degenerative disc disease—loss of hydration and structural integrity in intervertebral discs—compounded by facet joint arthritis and paraspinal muscle atrophy.
Chronic back pain frequently stems from degenerative disc disease—loss of hydration and structural integrity in intervertebral discs—compounded by facet joint arthritis and paraspinal muscle atrophy. Stem cell strategies target the nucleus pulposus (disc centre), where placental mesenchymal stem cells (MSCs) may regenerate proteoglycan matrix and restore biomechanical function. Exosomes derived from stem cells penetrate the avascular disc environment and deliver anti-inflammatory proteins that suppress catabolic pathways. Unlike surgical fusion, which immobilises segments, cell-based approaches aim to restore disc biology whilst preserving motion. MSCs also modulate neuropathic pain via immune suppression, addressing pain signalling independent of structural restoration. Thirty-five registered trials globally investigate disc regeneration and pain outcomes; two actively recruit new participants.
| Индикативна цена · България (ЕС) | €3,000–€8,000 |
|---|---|
| Глобален диапазон на пазарната цена | €4,600–€13,800 (dvcstem.com) |
| Основни видове клетки, които се изучават | MSCs from Amniotic Membrane, Exosomes |
| Статус на одобрение | Експериментален |
| Регистрирани проучвания (ClinicalTrials.gov) | 35 · 2 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published trials of intradiscal placental MSC injection demonstrate pain reduction (VAS or Oswestry scales) in 50–65% of participants over 6–12 months. Discography MRI findings show improved hydration signals in 30–50% of treated discs, interpreted as proteoglycan restoration, though correlation with pain outcomes is inconsistent. One phase II trial (67 patients) reported sustained pain relief at 24-month follow-up in 55% of injected discs. Exosome intra-discal delivery is emerging with small proof-of-concept studies showing reduced inflammatory biomarkers in disc fluid post-injection. Comparative data versus sham injection remain limited; most positive evidence derives from open-label or non-blinded designs.
Depending on assessment, a Back & Disc Degeneration protocol may draw on:
Intradiscal stem cell injection costs €4,500–7,000 per disc in European centres. Percutaneous or fluoroscopy-guided approaches command €5,000–6,500; minimally invasive endoscopic delivery may cost €6,500–7,500. Exosome-based disc therapy is priced similarly (€5,000–7,000). Most patients with multilevel disease require 2–3 treated discs, escalating total cost to €10,000–20,000. Few insurance schemes reimburse disc regeneration therapy; most classify as investigational. Out-of-pocket expense is expected, though some European countries (Spain, Portugal) offer selective reimbursement under medical necessity criteria.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Back & Disc Degeneration cost-by-country breakdown, or compare the best countries for Back & Disc Degeneration →
Before booking, check safety & regulation, the recovery climate, дали бихте могли да бъдете кандидат, and which cell type fits Back & Disc Degeneration.
Пълен Дегенерация на гърба и дискове ЧЗВ → · Разбор на разходите Дегенерация на гърба и дискове →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Съм ли кандидат? · Какъв тип клетки? · Types of clinics & best countries · Калкулатор на разходи
Медицински преглед от редакционния екип на StemCellAtlas с Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка